
Ivan Lieberburg MD
Diabetes, Lipid Metabolism
Professor of Medicine, University of California, San Francisco. Managing Director, Boxer Capital of the Tavistock Group. Director, Adamas Pharmaceuticals, Inc.
Join to View Full Profile
440 Stevens AveSuite 100Solana Beach, CA 92075
Phone+1 650-302-8344
Fax+1 858-400-3101
Dr. Lieberburg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1984
- University of California (San Francisco)Residency, Internal Medicine, 1980 - 1982
- University of Miami Leonard M. Miller School of MedicineClass of 1980
- Rockefeller University HospitalPost-Doctoral Fellowship, 1976 - 1978
- Rockefeller UniversityPh.D., Neurobiology, 1971 - 1976
- Cornell UniversityAB, Biology, 1967 - 1971
Certifications & Licensure
- FL State Medical License 1989 - Present
- CA State Medical License 1981 - 2021
- NY State Medical License 1984 - 2011
Awards, Honors, & Recognition
- Kaiser Teaching Award UCSF, 2009
- Neuroscience Fellow McKnight Foundation, 1985-1987
- Scholar Hartford Foundation, 1984-1987
- Join now to see all
Publications & Presentations
PubMed
- 70 citationsLethality of Alzheimer disease and its impact on nursing home placement.Henry Michael Arrighi, Peter J. Neumann, Ivan Lieberburg, Raymond J. Townsend
Alzheimer Disease and Associated Disorders. 2010-01-01 - 692 citationsFunctional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brainH. F. Dovey, V. John, J. P. Anderson, L. Z. Chen, P. De Saint Andrieu
Journal of Neurochemistry. 2009-04-22 - 1566 citationsPeripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.Frederique Bard, Catherine Cannon, Robin Barbour, Rae Lyn Burke, Dora Games
Nature Medicine. 2000-08-01
Press Mentions
- Adamas Announces Changes to Its Board of Directors with the Appointment of Spyros Papapetropoulos and the Retirement of Ivan LieberburgNovember 23rd, 2020
Research History
- Post-doctoral Fellow, UCSF1982 - 1984
- Post-doctoral FellowRockefeller University1976 - 1978
External Links
- Publicationshttp://www.ncbi.nlm.nih.gov/pubmed/?term=lieberburg
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: